1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Generics Bulletin Editor’s Picks For Q2 2023

Highlights Across The Off-Patent Sector From April To June 2023

 
• By Dave Wallace

Looking back over the second quarter of 2023, Generics Bulletin executive editor Dave Wallace picks out highlights from April to June that include strategic updates from some of the off-patent industry’s biggest players, several exclusive interviews, and the build-up to the second wave of biosimilar competition to Humira in the US.

Q2 second quarter post-it note on notice board
The second quarter of 2023 brought a number of key developments • Source: Shutterstock

The second quarter of 2023 brought a number of key developments for the generics and biosimilars sector, with major strategy updates offered by multiple industry-leading off-patent players.

One of these was Teva, which has been under the leadership of new CEO Richard Francis since the start of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Aurobindo Addresses Rumor Of $5bn Zentiva Buyout

 
• By Dave Wallace

Rumours are circulating that Aurobindo could be set to take ownership of Zentiva from current owner Advent in a $5bn transaction, which would represent one of the largest off-patent sector deals in some time.

Alvotech Focuses On Value Over Volume As Sales Continue To Grow

 
• By Dave Wallace

As Alvotech announced first-half results that outpaced expectations, the biosimilars developer’s management explained that the firm was targeting value and product margin over market share and volumes.

Accord Takes On Ustekinumab Rivals In US With Steepest Discount Yet

 
• By Dave Wallace

Boasting the “lowest WAC price among branded biosimilars to Stelara”, Accord BioPharma has launched its Imuldosa version of ustekinumab in the US at a 92% discount to the blockbuster immunology brand.

Zydus Looks To Ride gIbrance Exclusivity Wave; GLP-1 Battle-Ready With Differentiated Pen

 
• By Vibha Ravi

Ibrance is losing share to other drugs, but Zydus looks forward to a late 2027/early 2028 launch of its generic in the US where partner Synthon might have 180-day exclusivity. In India, as Lilly launches Mounjaro KwikPen, it hopes for a GLP-1 edge with a differentiated device and formulation.

More from Business

Formycon’s Search For Keytruda Biosimilar Partner Is Key To Deliver FY2025 Guidance

 
• By Urtė Fultinavičiūtė

With H1 revenues not even hitting double-digits, Formycon is bidding on partnerships and royalties to generate at least €46m over the next half-year to reach its revenue goal.

$160m War Chest Readied For Aquestive’s Oral Epinephrine Film Launch

 
• By Dean Rudge

Filed through the FDA’s 505(b)(2) hybrid new drug application pathway, Aquestive Therapeutics’ proposed Anaphylm (epinephrine) sublingual film has received major financial backing with a pair of funding deals.

Byooviz US Launch Slated For 2026 As Harrow Touts Immediate Uptake Potential

 
• By Dean Rudge

Harrow is taking aim at launching new partner Samsung Bioepis’ Byooviz biosimilar to Lucentis in 2026.